Survival and short-term outcome in newborns of 23 to 25 weeks' gestation.

OBJECTIVES: We determined which factors are associated with survival and good short-term neurologic outcome in newborns of 23 to 25 weeks' gestation. STUDY DESIGN: We retrospectively reviewed the charts of all (n = 82) infants born alive at our hospital at 23 to 25 weeks' gestation from 1988 through 1991. We used univariate and multiple logistic regression analysis to compare survivors at hospital discharge with nonsurvivors and those with and without good short-term neurologic outcome. RESULTS: Survival rates were 19%, 59%, and 65% at 23, 24, and 25 weeks' gestation, respectively. A total of 90% of survivors had good short-term neurologic outcome. On multiple logistic regression analysis, female sex (odds ratio 8.7, 95% confidence limits 2.2 and 34), larger birth weight (odds ratio 2.5 per 100 gm increment, 95% confidence limits 1.3 and 4.9), and more advanced gestational age (odds ratio 5.3, 95% confidence limits 1.2 and 22 for 24 weeks; odds ratio 3.8, 95% confidence limits 0.6 and 22 for 25 weeks) were associated with survival. Female sex, more advanced gestational age, and larger birth weight were also associated with good short-term neurologic outcome. CONCLUSIONS: Good short-term neurologic outcome is possible in many survivors in this gestational age range. Factors other than gestational age may be considered when intervention in these pregnancies is contemplated.

The frequency of hypoglycemia in full-term large and small for gestational age newborns.

Although various authors recommend screening for hypoglycemia in large for gestational age (LGA) and small for gestational age (SGA) newborns, the frequency of hypoglycemia in these infants, using a recent definition of hypoglycemia, and the proper duration of screening are not documented. We determined chromogen test strip blood glucose values at ages 1, 2, 3, 6, 12, 24, 36, and 48 hours in full-term LGA and SGA infants whose mothers were not diabetic. Serum glucose determination was immediately done if a test strip reading was less than 40 mg/dl. Hypoglycemia was defined as a serum glucose less than 35 mg/dl at less than 3 hours of age, less than 40 mg/dl at 3 to 24 hours of age, and less than 45 mg/dl at more than 24 hours of age. The frequency of hypoglycemia in LGA infants was 8.1% (95% confidence interval [CI] 5.0 to 11.2%), and in SGA infants, 14.7% (95% CI 9.8 to 19.6%). The mean age at which hypoglycemia occurred was 2.9 hours (range, 0.8 to 8.5) in LGA infants, and 6.1 hours (range, 0.8 to 34.2) in SGA infants. There were no differences in other possible risk factors between the hypoglycemic and euglycemic infants except that in SGA infants meconium-stained amniotic fluid (40% vs 20%, p = .001), maternal preeclampsia (27% vs 8%, p = 0.0056), and male sex (29% vs 9%, p = 0.029) were more common in hypoglycemic than in euglycemic infants. These data suggest that screening for hypoglycemia in LGA infants whose mothers are not diabetic may be stopped after 12 hours, but should continue for 48 hours in SGA infants.

Double versus single phototherapy in low birth weight newborns.

Conventional phototherapy systems that simultaneously irradiate the front and the back of the baby lower the serum bilirubin level more rapidly than one-sided systems, but they are impractical. Fiberoptic phototherapy makes it easy to administer conventional phototherapy from above while the infant lies on a fiberoptic phototherapy blanket. Newborns with birth weights less than 2500 g were randomly assigned to receive either single (n = 37) or double (n = 33) phototherapy. The groups were similar in clinical and laboratory characteristics. After 18 hours of therapy the serum bilirubin concentration declined by 31 +/- 11% in the double and 16 +/- 15% in the single phototherapy group (2.9 +/- 1.1 vs 1.6 +/- 1.4 mg/dL), and the difference in the total serum bilirubin levels after 18 hours of therapy was significant (double phototherapy group 7.1 +/- 2.7 mg/dL vs single phototherapy group 8.2 +/- 2.6 mg/dL). After 18 hours of treatment the serum bilirubin level was less than the phototherapy threshold level in 26 of 37 single phototherapy patients vs 32 of 33 double phototherapy patients. Double phototherapy was well tolerated. It is concluded that this type of double phototherapy is more effective than single phototherapy in low birth weight newborns. Double phototherapy may be useful when it is necessary to reduce an elevated serum bilirubin level as rapidly as possible or when the bilirubin level is rising with single phototherapy.

A clinical trial of fiberoptic phototherapy vs conventional phototherapy.

We conducted a randomized, controlled trial to compare fiberoptic phototherapy with conventional phototherapy in healthy jaundiced newborns with birth weights greater than 2500 g. Twelve patients received fiberoptic phototherapy and 14 patients received conventional phototherapy. There were no significant differences between the groups with respect to birth weight, gestational age, feeding method, presence of hemolytic disease, hematocrit, reticulocyte count, or initial serum bilirubin level. Measured irradiance at 425 to 475 nm for conventional phototherapy was greater than that of fiberoptic phototherapy (9.2 +/- 0.9 microW/cm2 per nanometer vs 8.2 +/- 1.2 microW/cm2 per nanometer). Both types of phototherapy lowered the level of serum bilirubin after 18 hours of therapy (fiberoptic group, from 231 +/- 29 to 210 +/- 24 mumol/L; conventional group, from 231 +/- 21 to 188 +/- 26 mumol/L), but the mean serum bilirubin level was lower after 18 hours of therapy in the conventional phototherapy group (188 +/- 26 vs 210 +/- 24 mumol/L). There were no side effects in either group of newborns. Both methods of phototherapy decreased the serum bilirubin level, but conventional phototherapy did so more effectively, probably because of its greater irradiance.

Complications associated with central venous catheters inserted in critically ill neonates.

OBJECTIVE: To assess the incidence and spectrum of complications associated with central venous catheter (CVC) placement in the critically ill infant. DESIGN: A prospective study of all babies hospitalized in a neonatal intensive care unit (NICU) from January 1989 to December 1989. Potential risk factors associated with infection were evaluated by a case-control comparison. SETTING: Conducted at a university-affiliated, tertiary care community hospital. PATIENTS: Neonates requiring intensive care and a central venous catheter. Controls consisted of noninfected babies. RESULTS: Of 263 critically ill neonates, only 13 (4.9%) required a CVC insertion. Seventeen CVCs were placed in these 13 neonates for a total duration of 600 days (median, 32 days/cannula). Fifteen (88%) of these cannulas had one or more complications during its catheter life including dislodgement or leakage (53%), occlusion or thrombosis (47%), infections (29%), or minor bleeding (12%). Five babies (29%) developed 6 episodes of bloodstream infection including 3 sporadic cases due to Staphylococcus epidermidis and a cluster of fungemia due to Malassezia furfur associated with lipid emulsion therapy. Infants with a CVC-associated infection were a younger gestational age (24 weeks versus 32 weeks, p = .04) and weighed less at birth (580 g versus 1285 g, p = .02). The overall rate of bloodstream infection was one episode per 100 days of catheter use. CONCLUSIONS: CVCs may be lifesaving to a critically ill neonate, but complications occur frequently. Use must be restricted to infants in whom alternate delivery routes of intravenous therapy or support are otherwise unavailable.

A comparison of chromogen test strip (Chemstrip bG) and serum glucose values in newborns.

Although glucose oxidase-peroxidase chromogen test strips are frequently used to estimate serum glucose values in newborns, previous studies have not evaluated multiobserver variability of test strip readings and have included few infants with hypoglycemia. We compared values of 272 samples of serum glucose with values simultaneously obtained by chromogen test strips (Chemstrip bG) in newborns. The diagnostic sensitivity of a chromogen test strip less than 2.2 mmol/L for predicting a serum glucose level less than 1.9 mmol/L was 86% (95% confidence interval [CI], 75% to 94%), with 78% specificity (95% CI, 73% to 84%). The positive predictive value in our specimens, with a 21% prevalence of serum glucose levels less than 1.9 mmol/L, was 52% (95% CI, 41% to 62%), with a negative predictive value of 95% (95% CI, 91% to 100%). Fifty-eight of our serum glucose values were less than 1.9 mmol/L and the levels obtained by chromogen test strip were greater than or equal to 2.2 mmol/L in 8 of these cases. Review of these 8 cases showed that a delay in performing the laboratory glucose oxidase serum glucose could account for the discrepancy in 2 cases. Chromogen test strips are readily available and easy to use, but more sensitive, specific, accurate, and precise methods of serum glucose screening in newborns are needed.